Skip to main content
OpenTrials

Clinical trial condition

Moderate to Severe Plaque-type Psoriasis

Explore clinical trials studying Moderate to Severe Plaque-type Psoriasis. Study availability and eligibility vary by location and protocol.

5 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Moderate to Severe Plaque-type Psoriasis trial results

Completed

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year

NCT01365455

Conditions
Arthritis, Arthritis, Psoriatic, Bone Diseases, +14 more
Locations
  • Novartis Investigative Site Birmingham, Alabama, United States
  • Novartis Investigative Site Birmingham, Alabama, United States
  • Novartis Investigative Site Phoenix, Arizona, United States
  • Novartis Investigative Site Los Angeles, California, United States
View all 88 locations
View Trial Details
Completed

Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis

NCT02474069

Conditions
Moderate to Severe Plaque-type Psoriasis, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, +6 more
Locations
  • Novartis Investigative Site Bad Bentheim, Germany
  • Novartis Investigative Site Berlin, Germany
  • Novartis Investigative Site Berlin, Germany
  • Novartis Investigative Site Berlin, Germany
View all 89 locations
View Trial Details
Completed

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

NCT01544595

Conditions
Dermatitis, Moderate to Severe Plaque-type Psoriasis, Psoriasis, +3 more
Locations
  • Novartis Investigative Site Birmingham, Alabama, United States
  • Novartis Investigative Site Birmingham, Alabama, United States
  • Novartis Investigative Site Phoenix, Arizona, United States
  • Novartis Investigative Site Phoenix, Arizona, United States
View all 182 locations
View Trial Details
Completed

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks

NCT01555125

Conditions
Moderate to Severe Plaque-type Psoriasis, Psoriasis, Skin Diseases, +2 more
Locations
  • Novartis Investigative Site Birmingham, Alabama, United States
  • Novartis Investigative Site Mobile, Alabama, United States
  • Novartis Investigative Site Glendale, Arizona, United States
  • Novartis Investigative Site Hot Springs, Arkansas, United States
View all 33 locations
View Trial Details
Completed

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

NCT01406938

Conditions
Dermatitis, Moderate to Severe Plaque-type Psoriasis, Pathological Conditions, Anatomical, +6 more
Locations
  • Novartis Investigative Site Fresno, California, United States
  • Novartis Investigative Site Pasadena, California, United States
  • Novartis Investigative Site Sacramento, California, United States
  • Novartis Investigative Site San Francisco, California, United States
View all 131 locations
View Trial Details

Related conditions